NO2648726T3 - - Google Patents
Info
- Publication number
- NO2648726T3 NO2648726T3 NO11805292A NO11805292A NO2648726T3 NO 2648726 T3 NO2648726 T3 NO 2648726T3 NO 11805292 A NO11805292 A NO 11805292A NO 11805292 A NO11805292 A NO 11805292A NO 2648726 T3 NO2648726 T3 NO 2648726T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42059910P | 2010-12-07 | 2010-12-07 | |
PCT/US2011/063817 WO2012078805A1 (en) | 2010-12-07 | 2011-12-07 | Polycyclic lpa1 antagonist and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2648726T3 true NO2648726T3 (da) | 2018-09-01 |
Family
ID=45446189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO11805292A NO2648726T3 (da) | 2010-12-07 | 2011-12-07 |
Country Status (25)
Country | Link |
---|---|
US (2) | US9556133B2 (da) |
EP (2) | EP3360552A1 (da) |
JP (1) | JP6030567B2 (da) |
KR (1) | KR101875246B1 (da) |
CN (2) | CN107721940A (da) |
AU (2) | AU2011338417B2 (da) |
BR (1) | BR112013013950A2 (da) |
CA (1) | CA2820884A1 (da) |
CY (1) | CY1120342T1 (da) |
DK (1) | DK2648726T3 (da) |
EA (1) | EA024967B1 (da) |
ES (1) | ES2674174T3 (da) |
HR (1) | HRP20180970T1 (da) |
HU (1) | HUE040397T2 (da) |
IL (1) | IL226698B (da) |
LT (1) | LT2648726T (da) |
MX (1) | MX347544B (da) |
NO (1) | NO2648726T3 (da) |
PL (1) | PL2648726T3 (da) |
PT (1) | PT2648726T (da) |
RS (1) | RS57377B1 (da) |
SG (1) | SG191041A1 (da) |
SI (1) | SI2648726T1 (da) |
TR (1) | TR201809293T4 (da) |
WO (1) | WO2012078805A1 (da) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20140879A1 (es) | 2010-12-07 | 2014-08-06 | Amira Pharmaceuticals Inc | Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis |
AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
RU2649398C2 (ru) | 2012-12-28 | 2018-04-03 | Убе Индастриз, Лтд. | Галогензамещенное гетероциклическое соединение |
US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
DK3003038T3 (da) | 2013-06-07 | 2019-11-11 | Scripps Research Inst | 2h-1,2,3-triazolderivater som inhibitorer af fibrose |
US9987381B2 (en) | 2013-10-31 | 2018-06-05 | Bristol-Myers Squibb Company | Radioligands for imaging the LPA-1 receptor |
HUE045209T2 (hu) * | 2013-12-04 | 2019-12-30 | Galmed Res & Development Ltd | Aramchol-sók |
GB201410741D0 (en) * | 2014-06-17 | 2014-07-30 | Babraham Inst And University Of Birmingham The | Novel diagnostic and therapeutic method |
CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
WO2016197009A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
WO2017086430A1 (ja) * | 2015-11-20 | 2017-05-26 | 宇部興産株式会社 | Nashの治療又は予防のための医薬組成物 |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
CN108318447B (zh) * | 2018-05-04 | 2020-12-18 | 山东大学 | 一种基于近红外光谱技术快速测定吡喹酮对映体组成的方法 |
CA3102683A1 (en) | 2018-06-07 | 2019-12-12 | Idorsia Pharmaceuticals Ltd | Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis |
KR102224677B1 (ko) * | 2018-08-23 | 2021-03-08 | 가천대학교 산학협력단 | 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 |
JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのオキサビシクロ酸 |
AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
KR20220101137A (ko) | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
US20230000846A1 (en) | 2019-12-04 | 2023-01-05 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
CN111608208B (zh) * | 2020-05-19 | 2022-01-11 | 浙江鲁班建材科技股份有限公司 | 一种时间可控制的吸水膨胀堵漏型预铺卷材 |
TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
KR102463504B1 (ko) | 2022-08-23 | 2022-11-04 | 주식회사 에네스지 | 원전 습분분리재열기의 종단온도차 보정 방법 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
WO2001060819A1 (fr) * | 2000-02-18 | 2001-08-23 | Kirin Beer Kabushiki Kaisha | Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments |
US20030215462A1 (en) | 2001-12-21 | 2003-11-20 | Wacher Vincent J. | Use of UGT inhibitors to increase bioavailability |
US20040014648A1 (en) | 2002-05-17 | 2004-01-22 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
CN1791592B (zh) | 2003-05-19 | 2012-07-04 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
EP1915369A4 (en) | 2005-08-11 | 2010-09-08 | Merck Frosst Canada Ltd | NEW SUBSTITUTED 1,2,3-TRIAZOLYLMETHYLBENZOTHIOPHENE OR ENDOLE AND THEIR USE AS INHIBITORS OF LEUKOTRIENBIOSYNTHESIS |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
WO2007087250A2 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
-
2011
- 2011-12-07 PL PL11805292T patent/PL2648726T3/pl unknown
- 2011-12-07 EP EP18163527.7A patent/EP3360552A1/en not_active Withdrawn
- 2011-12-07 CN CN201710849870.XA patent/CN107721940A/zh active Pending
- 2011-12-07 CN CN201180066933.5A patent/CN103596566B/zh not_active Expired - Fee Related
- 2011-12-07 KR KR1020137017670A patent/KR101875246B1/ko active IP Right Grant
- 2011-12-07 TR TR2018/09293T patent/TR201809293T4/tr unknown
- 2011-12-07 EA EA201390840A patent/EA024967B1/ru not_active IP Right Cessation
- 2011-12-07 EP EP11805292.7A patent/EP2648726B1/en active Active
- 2011-12-07 RS RS20180740A patent/RS57377B1/sr unknown
- 2011-12-07 SI SI201131465T patent/SI2648726T1/en unknown
- 2011-12-07 MX MX2013006394A patent/MX347544B/es active IP Right Grant
- 2011-12-07 BR BR112013013950A patent/BR112013013950A2/pt not_active IP Right Cessation
- 2011-12-07 LT LTEP11805292.7T patent/LT2648726T/lt unknown
- 2011-12-07 HU HUE11805292A patent/HUE040397T2/hu unknown
- 2011-12-07 NO NO11805292A patent/NO2648726T3/no unknown
- 2011-12-07 WO PCT/US2011/063817 patent/WO2012078805A1/en active Application Filing
- 2011-12-07 DK DK11805292.7T patent/DK2648726T3/da active
- 2011-12-07 ES ES11805292.7T patent/ES2674174T3/es active Active
- 2011-12-07 PT PT118052927T patent/PT2648726T/pt unknown
- 2011-12-07 AU AU2011338417A patent/AU2011338417B2/en not_active Ceased
- 2011-12-07 JP JP2013543325A patent/JP6030567B2/ja not_active Expired - Fee Related
- 2011-12-07 US US13/992,022 patent/US9556133B2/en active Active
- 2011-12-07 CA CA2820884A patent/CA2820884A1/en not_active Abandoned
- 2011-12-07 SG SG2013043740A patent/SG191041A1/en unknown
-
2013
- 2013-06-02 IL IL226698A patent/IL226698B/en not_active IP Right Cessation
-
2016
- 2016-10-05 AU AU2016238848A patent/AU2016238848B2/en not_active Ceased
- 2016-12-16 US US15/381,562 patent/US20170121295A1/en not_active Abandoned
-
2018
- 2018-06-08 CY CY20181100603T patent/CY1120342T1/el unknown
- 2018-06-27 HR HRP20180970TT patent/HRP20180970T1/hr unknown